Thermalin’s portfolio of next-generation insulin analogs fills multiple gaps in a rapidly growing $25B market. Thermalin’s world-class team is leveraging breakthroughs with significant IP built on 25 years of research on insulin by Dr. Michael Weiss, Chairman of Biochemistry and Molecular Biology at Indiana University Medical School. Our new molecules, novel formulations, and devices address unmet clinical needs, enable new delivery technologies and reach rapidly developing markets. In July, 2017, Thermalin entered into a license and collaboration agreement with Sanofi for 2 of our 7 insulin programs. For more information, please contact Richard Berenson (firstname.lastname@example.org).